NASDAQ: KPTIKaryopharm Therapeutics Inc Stock
$1.28-0.10 (-7.25%)
Updated Apr 18, 2024
KPTI Price
$1.28
Fair Value Price
N/A
Market Cap
$147.29M
52 Week Low
$0.62
52 Week High
$4.11
P/E
-1.02x
P/B
-1.08x
P/S
0.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$146.03M
Earnings
-$143.10M
Gross Margin
96.6%
Operating Margin
-81.46%
Profit Margin
-98%
Debt to Equity
-2.77
Operating Cash Flow
-$93M
Beta
1.43
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KPTI Overview
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KPTI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KPTI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KPTI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
KPTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KPTI due diligence checks available for Premium users.
Be the first to know about important KPTI news, forecast changes, insider trades & much more!
KPTI News
Valuation
KPTI fair value
Fair Value of KPTI stock based on Discounted Cash Flow (DCF)
Price
$1.28
Fair Value
$1.57
Undervalued by
18.25%
KPTI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KPTI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.02x
Industry
15.68x
Market
41.33x
KPTI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.08x
Industry
5.76x
KPTI's financial health
Profit margin
Revenue
$33.7M
Net Income
-$41.8M
Profit Margin
-124%
KPTI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KPTI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$240.4M
Liabilities
$376.6M
Debt to equity
-2.77
KPTI's short-term assets ($233.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPTI's long-term liabilities ($307.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPTI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPTI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.6M
Investing
$26.8M
Financing
$264.0k
KPTI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KPTI vs Biotech Stocks
Karyopharm Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.